BioCardia/ US09060U6064 /
| 2024-09-06 9:59:15 PM | Chg. -0.26 | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 2.25USD | -10.36% | 3 Turnover: 6.75 |
-Bid Size: - | -Ask Size: - | 2.25 | 2.25 |
GlobeNewswire
08-30
BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasda...
GlobeNewswire
08-29
BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family
GlobeNewswire
08-21
FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analys...
GlobeNewswire
08-07
BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024
GlobeNewswire
07-30
BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family
GlobeNewswire
07-25
Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of ...
GlobeNewswire
07-17
BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter ...
GlobeNewswire
07-08
CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatm...
GlobeNewswire
06-07
BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to ...
GlobeNewswire
05-09
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024
GlobeNewswire
05-01
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in...
GlobeNewswire
04-25
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Isch...
GlobeNewswire
03-27
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
GlobeNewswire
03-20
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
GlobeNewswire
03-12
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart ...
GlobeNewswire
03-04
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial,...
GlobeNewswire
02-08
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved ...
GlobeNewswire
01-03
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Share...
GlobeNewswire
2023-12-19
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchym...
